Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalation of Imipenem/Cilastatin plus Vancomycin Therapy for Critically Ill Patients with Hospital-Acquired Pneumonia
KCT0000065Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2004
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of imipenem + cilastatin, vancomycin in hospital-acquired pneumonia (HAP), sponsored by Merck & Co.. Started Nov 2004; status: completed.
02
Drugs
imipenem + cilastatinvancomycin
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on KCT0000065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000065.